Implications of pharmacogenomics for drug development

Experimental Biology and Medicine

Volumn 233, Issue 12, 2008, Pages 1484-1497

  Kirk, Randal J ^a   Hung, Jeffrey L ^a   Horner, Scott R ^a   Perez, Jeffrey T ^a  

^a Third Security LLC   (United States)

Author keywords

Biomarkers; Clinical trials; Drug development; Metabolizers; Pharmacogenomics

Indexed keywords

17 ALLYAMINO 17 DEMETHOXYGELDANAMYCIN; ADVEXIN; AVN 944; BIOLOGICAL MARKER; CELECOXIB; CETUXIMAB; CIPROFLOXACIN; CLARITHROMYCIN; CNF 1010; DEBRISOQUINE; DOXEPIN; ERLOTINIB; FLUOXETINE; GEFITINIB; GEMCITABINE; GEMIFLOXACIN; IMATINIB; IRINOTECAN; PANITUMUMAB; PAROXETINE; PERHEXILINE; ROFECOXIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VALDECOXIB; VILAZODONE; WARFARIN; NEW DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL EDUCATION; CLINICAL MEDICINE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG METABOLISM; DRUG RESEARCH; ECONOMICS; HISTORY OF MEDICINE; HUMAN; METHODOLOGY; PATENT; PHARMACOGENOMICS; STATISTICAL ANALYSIS; CHEMISTRY; CLINICAL PHARMACOLOGY; DRUG DESIGN; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GENOMICS; HISTORY; PHARMACEUTICS; PHARMACOGENETICS; REVIEW; UNITED STATES;

CHEMISTRY, PHARMACEUTICAL; CLINICAL MEDICINE; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; GENOMICS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 58749097312     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0805-S-150     Document Type: Conference Paper

References (55)

1. Burger A. Burgers medicinal chemistry and drug discovery (6th ed.). In: Abraham DJ, ed. Drug Discovery. ISBN 0-471-27090-3. Hoboken, NJ: John Wiley & Sons, Inc., Vol 1, 2003.
2. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348; 6:538-549, 2003.
3. Kalow W, Tang BK, Endrenyi I. Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8:283-289, 1998.
4. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci 2; 1:1-13, 2000. Accessed on February 1, 2008 from the World Wide Web: http://aapspharmsci.org/articles/ps0201/ps020104/ ps020104.pdf.
5. Ford EB. Genetic polymorphism. London: Faber & Faber, 1965.
6. Sweeney BP. Pharmacogenomics: the genetic basis for variability in drug response. In: Cashman JN, Grounds RM, Eds. Recent Advances in Anaesthesia and Intensive Care. United Kingdom: Cambridge University Press, Vol 23:pp1-34, 2005.
7. Vogel F. Moderne probleme der humangenetik. Ergeb Inn Med Kinderheilkd 12:52-125, 1959.
8. Council for International Organizations of Medical Sciences (CIOMS). Pharmacogenetics: towards improving treatment with medicines. Switzerland, 2005.
9. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB. Integrating genotype and phenotype information: an overview of the PharmGKB Project. Pharmacogenomics J 1:167-170, 2001.
10. Stanford University. (2007). PharmGKB: The pharmacogenetics and pharmacogenomics knowledge base. Retrieved January 31, 2008 from the World Wide Web: http://www.pharmgkb.org.
11. National Center for Biotechnology Information. (17 Jan. 2008). dbSNP Home Page. Retrieved February 1, 2008 from the World Wide Web: http://www.ncbi.nlm. nih.gov/projects/SNP.
12. International HapMap Project (20 Dec. 2007). HapMap Homepage. Retrieved February 1, 2008 from the World Wide Web: http://www.hapmap.org.
13. Frost & Sullivan. (Oct. 2004). Strategic analysis of biomarkers in clinical trials.
14. Technology Review. (30 Jan. 2008). Genetic variant predicts heart disease risk. Retrieved February 5, 2008 from the World Wide Web: http://www. technologyreview.com/Biotech/20130/?nlid=856.
15. Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, Simonsen KL, Kirchgessner TG, Cannon CP, Devlin JJ, Braunwald E. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes. JACC 51:449-455, 2008.
16. O'Dwyer PJ, Catalano RB. Uridine Diphosphate Glucoronosyltransfer-ase (UGT) 1A1 and Irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24; 28:4534-4538, 2006.
17. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren L, Burrows F. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 5; 5:1256-1264, 2006.
18. Clinical Data. (30 Mar. 2006). Clinical data initiates patient enrollment for Vilazodone Phase 3 clinical trial. Retrieved January 31, 2008 from the World Wide Web: http://www.clda.com/uploads/vilaz%20ph3%20-mar%2030.pdf.
19. Congress of the United States Congressional Budget Office. (October 2006). Research and development in the pharmaceutical industry. Retrieved April 2, 2008 from the World Wide Web: http://www.cbo.gov/ftpdocs/76xx/doc76151/10-02- DrugR-D.pdf
20. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 449:851-861, 2007.
21. Human genomes, public and private. Nature 409:745-964, 2001.
22. NIH News Release. NHGRI seeks next generation of sequencing technologies. Retrieved April 2, 2008 from the World Wide Web: http://www.genome.gov/ 12513210.
23. U.S. Food and Drug Administration. Public health advisory: non-steroidal anti-inflammatory drug products (NSAIDS). Retrieved May 6, 2008 from the World Wide Web: http://www.fda.gov/cder/drug/advisory/nsaids.htm.
24. Greener M. Drug safety on trial. EMBO Reports 6; 3:202-204, 2005.
25. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med 349:908-909, 2003.
26. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AAM, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103:89-95, 2001.
27. Arizona Center for Education and Research on Therapeutics. (25 Mar. 2008). QT drug lists by risk groups. Retrieved May 6, 2008 from the World Wide Web: http://www.qtdrugs.org/medical-pros/drug-lists/drug-lists.cfm.
28. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5:262-270, 2005.
29. Wadelius M, Sörlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PKE, Wadelius C, Melhus H. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 4: 40-48, 2004.
30. U.S. Food and Drug Administration. FDA approves updated warfarin (coumadin) prescribing information. Retrieved May 6, 2008 from the World Wide Web: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html.
31. U.S. Food and Drug Administration. Critical path initiative: warfarin
32. dosing. Retrieved May 6, 2008 from the World Wide Web: http://www.fda.gov/oc/initiatives/criticalpath/warfarin.html.
33. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials (3rd ed.). New York: Springer-Verlag, pp100-103, 2005.
34. PRNewswire. (12 Oct. 2006). Phase 3 clinical trial costs exceed $26,000 per patient. Retrieved February 8, 2008 from the World Wide Web:http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/ 10-12-2006/0004450180&EDATE=
35. Sallustio BC, Westley IS, Morris RG Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol 54:107-114, 2002.
36. PricewaterhouseCoopers. Personalized medicine: the emerging phar-macogenomics revolution. 2005.
37. Department of Health and Human Services. Realizing the promise of pharmacogenomics: opportunities and challenges (draft report of the Secretary's Advisory Committee on Genetics, Health, and Society). Retrieved May 6, 2008 from the World Wide Web: http://www4.od.nih.gov/oba/sacghs/SACGHS-PGx-PCdraft.pdf.
38. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 22:151-185, 2003.
39. Gilbert J, Henske P, Singh A. Rebuilding big pharma's business model. In Vivo: The Business & Medicine Report 21;10, 2003.
40. Dickson M, Gagnon JP. The cost of new drug discovery and development. Discov Med 4; 22:172-179, 2004.
41. The Boston Consulting Group. A revolution in R&D: how genomics and genetics are transforming the biopharmaceutical industry. November 2001.
42. DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics 28:469-479, 2007.
43. National Institutes of Standards and Technology. (November 2007).Economic analysis of the technology infrastructure needs of the U.S. biopharmaceutical industry. Retrieved February 11, 2008 from the World Wide Web: http://www.nist.gov/director/prog-ofc/report07-1.pdf.
44. U.S. Food and Drug Administration. (January 2007). FDA's critical path initiative-science enhancing the health and well-being of all Americans. Retrieved February 11, 2008 from the World Wide Web: http://www.fda.gov/oc/ initiatives/criticalpath/initiative.html.
45. Temple RJ. Use of genomic biomarkers in a regulatory environment. DIA Genomic Biomarker. Oct. 7, 2005.
46. Temple RJ. Use of enrichment designs to promote efficiency. NIH Roadmap Workshop. Aug. 1, 2007. Retrieved February 11, 2008 from the World Wide Web: http://nihroadmap.nih.gov/molecularlibraries/workshop2007.
47. Guo Y, Shafer F, Weller P, Usuka J, Peltz G. Pharmacogenomics and drug development. Pharmacogenomics 6; 8:857-864, 2005.
48. Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Web Exclusives) W3:521-W3:536, 2003.
49. National Coalition for Health Professional Education in Genetics. Retrieved May 5, 2008 from the World Wide Web: http://www.nchpeg.org/index.asp.
50. American Academy of Family Physicians. Retrieved May 5, 2008 from the World Wide Web: http://www.aafp.org/online/en/home/clinical/acf/genomics.html.
51. Lowe D. What you need to know about adaptive trials. Pharmaceutical Executive, Jul 1, 2006.
52. Usdin S. Proof is in the pudding. Biocentury 16; 14:A1-A6, 2008.
53. Gage BF, Eby CS. The genetics of vitamin K antagonists. Pharmacogenomics J 4:224-225, 2004.
54. Press M, Seelig SA. Lessons learned from the development of a diagnostic to predict response to Herceptin. Targeted medicine: from concept to clinic sympsosium, November 2004.
55. Tarceva (erlotinib) package insert. Retrieved June 9, 2008 from the World Wide Web: http://www.fda.gov/cder/foi/label/2004/021743lbl.pdf.